E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, stiffness, and loss of function in your joints |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10039073 |
E.1.2 | Term | Rheumatoid arthritis |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the long-term safety of GDC-0853 over an extended treatment period of up to 52 weeks
• To evaluate the efficacy of GDC-0853 (analysed separately for methotrexate-inadequate response [MTX-IR] and tumour necrosis factor-inadequate response [TNF-IR] patients) at Week 52 relative to baseline in Study GA29350
|
|
E.2.2 | Secondary objectives of the trial |
• To determine the improvement in disease activity through 52 weeks of treatment (analysed separately for MTX-IR and TNF-IR patients) relative to baseline in Study GA29350
• To assess Disease Activity Score (DAS28) remission (< 2.6) and Low-disease activity [LDA] (< 3.2) state
• To assess American College of Rheumatology (ACR)/European League
Against Rheumatism (EULAR) remission according to the Boolean-based
definition
• To assess simplified disease activity index (SDAI)-based remission (ACR/EULAR remission) and clinical disease activity index (CDAI)-based remission
• To assess efficacy based on the individual components of theACR relative to baseline in Study GA29350
• To evaluate the effect of GDC-0853 on health-related quality of life and on fatigue
• To characterize the pharmacokinetics (PK) of GDC-0853 in patients using a population PK approach
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age 18 to 76
- Completion of treatment period through Day 84 as specified in Study
GA29350
- Acceptable safety and tolerability during Study GA29350 as determined by the investigator or Medical Monitor
- Have not received any prohibited medications in Study GA29350
- While taking MTX, must be willing to receive oral folic acid (at least 5 milligram [mg]/week)
|
|
E.4 | Principal exclusion criteria |
- Met protocol defined treatment stopping criteria during Study GA29350
- Treatment with any investigational agent (other than study drug) or live/attenuated vaccine during Study GA29350 or since the last administration of study drug in Study GA29350
- In the opinion of the investigator, any new (since initially enrolling in the Phase II Study GA29350), significant, uncontrolled comorbidity, such as neurological, cardiac (e.g., moderate to severe heart failure New York Heart Association [NYHA] Class III/IV), pulmonary, renal, hepatic, endocrine, or GI disorders (excluding RA) that would increase the risk to the patient in Study GA30067
- Pregnant or lactating, or intending to become pregnant during the study
- Any uncontrolled or clinically significant laboratory abnormality that would affect safety, interpretation of study data, or the patient’s participation in the study in the opinion of the investigator
- Patients who experienced a de novo or reactivated serious viral infection such as hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV during the Phase II Study GA29350
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety:
1. Incidence of adverse events
2. Changes in vital signs, physical findings, ECGs, and clinical laboratory results during and following GDC-0853 administration
Efficacy:
3. ACR50 response at Week 52
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Safety:
1-2. Up to 60 weeks
Efficacy:
3. Week 52
|
|
E.5.2 | Secondary end point(s) |
Efficacy:
1. ACR50 response up to Week 12
2. ACR20 and ACR70
3. Disease Activity Score (DAS) 28-3 C-reactive protein (CRP) and DAS 28-4 (CRP) responder rates
4. DAS 28-3 (Erythrocyte Sedimentation Rate [ESR]) and DAS 28-4 (ESR) responder rates
5. DAS28 remission (< 2.6) and LDA (< 3.2) state
6. Boolean based remission
7. Simplified disease activity index-based remission
8. Clinical disease activity index-based remission status
9. Response rates for tender/painful joint count (68) and swollen joint count (66)
10. Patient’s Assessment of Arthritis Pain
11. Patient’s Global Assessment of Arthritis
12. Physician’s Global Assessment of Arthritis
13. CRP
14. Health assessment questionnaire–Disability Index
15. Short-Form 36 Health Survey, standard, Version 2, questionnaire
16. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
PK:
17. Area under the concentration time-curve from time 0 to time t (AUC0-t)
18. Minimum observed plasma concentration (Ctrough)
19. Half-life, apparent (t1/2)
20. Clearance following oral dosing (CL/F)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Efficacy:
1. Up to Week 12
2-16. Up to Week 52
PK:
17-20. Day (D) 1, D84, D365 and early termination or an unscheduled visit
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 37 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Brazil |
Bulgaria |
Chile |
Colombia |
Korea, Republic of |
Mexico |
Poland |
Russian Federation |
Serbia |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of this study is defined as the date when the last patient, last visit (LPLV) occurs or the date at which the last data point required for statistical analysis or safety follow-up is received from the last patient, whichever occurs later. LPLV is expected to occur approximately 60 weeks after the last patient is enrolled. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |